It was not a full halt, it was a partial halt. Clearly the FDA anticipated that meant the trial would continue with already enrolled patients. That’s a false assumption.
It was not because of safety of the treatment, and if it were, they’d have had a duty to warn.
In other words, it was not the FDA’s intention that they stop the trial or treatments at all, clearly. If that had been the intention, we’d have known and NWBO would have had no other options but to stop, but for extenuating circumstances.... and those would have been communicated clearly built the regulators for the benefit of the patients with whom the FDA has the firmest of duties.